Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus EMFLAZA.
ASMANEX HFA vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid